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Abstract: Tumors with histological features of pilocytic astrocytoma (PA), but with increased
mitotic activity and additional high-grade features (particularly microvascular
proliferation and palisading necrosis) are often designated anaplastic pilocytic
astrocytomas (APAs). The status of APA as a separate entity has not yet been clarified
and molecular features have only been partially characterized. We performed DNA
methylation profiling of 102 tumors with the histological differential diagnosis of APA. T-
distributed stochastic neighbor embedding (t-SNE) and hierarchical clustering analysis
of these 102 cases against 158 reference cases from 12 glioma reference DNA
methylation classes revealed that a subset of 83 of these tumors form a DNA
methylation class distinct from the reference classes. These 83 tumors were thus
defined as DNA methylation class APA (MC APA). The 19 remaining tumors were
distributed amongst the reference classes. Among these, in 11 tumors the molecular
diagnosis could be further confirmed by additional analyses, whereas 8 remained non-
classifiable. Median age of patients with MC APA was 41.5 years. The most frequent
localization was the posterior fossa (74%). Deletions of CDKN2A/B (66/83, 80%),
MAPK pathway gene alterations (49/65, 75%, most frequently affecting NF1, followed
by BRAF and FGFR1) and mutations of ATRX or loss of ATRX expression (33/74,
45%) were the most common molecular alterations. All tumors were IDH1/2 wildtype.
The MGMT promoter was methylated in 38/83 tumors (45%). Outcome analysis
confirmed an unfavorable clinical course compared with PA, but better than IDH
wildtype glioblastoma (GBM). In conclusion, we show that APAs carry a distinct DNA
methylation profile, frequent alterations in MAPK pathway genes (particularly NF1) in
combination with alterations of CDKN2A/B and ATRX, affect patients who are on
average older than those with PA and have an intermediate clinical outcome.
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Abstract 
Tumors with histological features of pilocytic astrocytoma (PA), but with increased mitotic 
activity and additional high-grade features (particularly microvascular proliferation and 
palisading necrosis) are often designated anaplastic pilocytic astrocytomas (APAs). The status 
of APA as a separate entity has not yet been clarified and molecular features have only been 
partially characterized. We performed DNA methylation profiling of 102 tumors with the 
histological differential diagnosis of APA. T-distributed stochastic neighbor embedding (t-SNE) 
and hierarchical clustering analysis of these 102 cases against 158 reference cases from 12 
glioma reference DNA methylation classes revealed that a subset of 83 of these tumors form 
a DNA methylation class distinct from the reference classes. These 83 tumors were thus 
defined as DNA methylation class APA (MC APA). The 19 remaining tumors were distributed 
amongst the reference classes. Among these, in 11 tumors the molecular diagnosis could be 
further confirmed by additional analyses, whereas 8 remained non-classifiable. Median age of 
patients with MC APA was 41.5 years. The most frequent localization was the posterior fossa 
(74%). Deletions of CDKN2A/B (66/83, 80%), MAPK pathway gene alterations (49/65, 75%, 
most frequently affecting NF1, followed by BRAF and FGFR1) and mutations of ATRX or loss 
of ATRX expression (33/74, 45%) were the most common molecular alterations. All tumors 
were IDH1/2 wildtype. The MGMT promoter was methylated in 38/83 tumors (45%). Outcome 
analysis confirmed an unfavorable clinical course compared with PA, but better than IDH 
wildtype glioblastoma (GBM). In conclusion, we show that APAs carry a distinct DNA 
methylation profile, frequent alterations in MAPK pathway genes (particularly NF1) in 
combination with alterations of CDKN2A/B and ATRX, affect patients who are on average older 
than those with PA and have an intermediate clinical outcome. 
Key words 
anaplastic pilocytic astrocytoma; pilocytic astrocytoma with anaplasia; methylation profile 
based classification; panel sequencing; ATRX; BRAF; NF1; FGFR1; MGMT; CDKN2A/B; IDH-
wildtype; molecular characterization; DNA copy number alterations 
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Introduction 
PA accounts for approximately 5% of gliomas across all age groups and for approximately 
25% of all brain tumors encountered in pediatric neurosurgical practice [9, 48], thereby 
representing the most common primary brain tumor in patients of 0 to 19 years of age. In 
contrast, the majority of gliomas in adults are either diffuse gliomas with IDH1 mutation (either 
1p19q co-deleted or 1p19q intact) or highly malignant GBMs [52]. Where gross total resection 
is feasible, clinical outcome of PA is usually favorable with 10 year overall survival rates of 
around 95% [9, 10, 14, 42]. The vast majority of PAs harbor single genetic alterations in genes 
encoding proteins of the mitogen-activated protein kinase (MAPK) pathway. The most frequent 
molecular findings in PAs are fusions of BRAF with KIAA1549 or rarely other genes, BRAF 
V600E point mutation or alterations of NF1, FGFR1 or NTRK family genes [24]. Different 
localizations of PA are associated with different frequencies of molecular alterations with 
posterior fossa tumors harboring a BRAF fusion in up to 80-90% of cases and supratentorial 
lesions showing this alteration in only about 60% of cases [21, 22]. Of further interest is the 
reported age association of BRAF fusions that seem to be less frequent in the adult population 
(e.g. 30% of patients of 31-40 years and 7% of patients older than 40 years of age) [17, 22]. 
To date, BRAF gene alterations are considered a molecular hallmark of WHO grade I PA with 
a typically favorable outcome [18, 21, 44]. Rare cases of PA, particularly in older patients, can 
have a more aggressive clinical behavior [4, 6, 41, 42, 48, 55]. The tumors of these patients 
may show anaplastic histological features including increased nuclear atypia, increased mitotic 
activity, prominent endothelial proliferation and/or palisading necrosis and have been 
discussed to represent a separate entity or subentity [42]. In the WHO classification 2016, this 
glioma subgroup is designated pilocytic astrocytoma with anaplasia. The identification of this 
particular subset of more aggressively behaving tumors is challenging, as the histological 
features described in the WHO classification do not exclude the diagnosis of conventional PA 
WHO grade I [9, 42], while histological overlap with pleomorphic xanthoastrocytoma/anaplastic 
pleomorphic xanthoastrocytoma and GBM has also been described. Moreover, according to 
the WHO classification, grading and nomenclature of pilocytic astrocytoma with anaplasia are 
still to be defined [1]. One study on the molecular characterization of clinically 
aggressive/recurrent or histologically defined APA revealed a heterozygous PTEN/10q loss in 
6 of 19 (32%) and a homozygous CDKN2A/B deletion in 3 of 15 (20%) cases. In this cohort, 
BRAF fusions were identified in 63% of cerebellar lesions [41]. A different study observed an 
association with neurofibromatosis type I in 28% of APA [16]. Nevertheless, more 
comprehensive approaches are necessary to establish a molecular profile. 
Recently, DNA methylation profiling became an important adjunct tool for tumor classification 
and identification of molecular subclasses [19, 30, 32, 33, 43, 46, 49]. To further characterize 
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APA, we analyzed a retrospective series of 102 cases with histological features of APA by 
DNA methylation profiling, DNA copy number analysis, next generation gene panel sequencing 
as well as by histological characterization and correlated these data with clinical information. 
Herein, we report that a major subset (83/102, 81%) of these cases form a distinct DNA 
methylation class, harbor frequent MAPK pathway gene alterations and have additional 
molecular and clinical features that clearly distinguish them from WHO grade I PAs as well as 
from other adult diffuse gliomas - thereby warranting their classification as a separate entity.  
Materials and Methods 
Tissue samples 
Formalin fixed and paraffin embedded tissue of 102 retrospective cases with histological 
features compatible with the diagnosis of APA were retrieved from the archives of several large 
Neuropathology departments: the Department of Neuropathology, University Hospital 
Heidelberg; the Department of Neurosurgery, University Hospital of Mannheim; the 
Department of Neuropathology, Charité Universitätsmedizin Berlin; the Department of 
Neuropathology, University of Bonn; the Department of Neuropathology, Heinrich Heine 
University Duesseldorf; the Institute for Neuropathology, University of Essen; the Institute for 
Neuropathology, University of Freiburg; the Institute of Neuropathology, University of Giessen; 
the Department of Neuropathology, Hannover Medical School; the Department of 
Neuropathology, University of Cologne; the Department of Neuropathology, Leipzig University; 
the Institute for Neuropathology, University of Münster; the Institute for Pathology and 
Neuropathology, University of Tübingen; the Department of Neuropathology, University of 
Würzburg; the Institute for Neuropathology, the Department of Neurology, University Hospital 
and University of Zurich; the Institute of Pathology, University of Bern; the Division of 
Neuropathology of the Johns Hopkins School of Medicine, Baltimore, Maryland, USA; the 
Mayo Clinic, Rochester, Minnesota, USA; the Division of Neuropathology, UCL Institute of 
Neurology in London; the Department of Cellular Pathology, Queen’s Hospital, Romford. In 
addition, we obtained material via the German Glioma Network. Tissue collection and 
processing as well as data collection were performed in compliance with local ethics 
regulations and approval. 
Clinical data 
The following clinical data were acquired, when possible: referred histological diagnosis, 
patient gender, age at diagnosis of APA, localization, manifestation (primary lesion or recurrent 
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lesion), history of a precursor lesion, history of irradiation, presence of a tumor predisposition 
syndrome, progression-free survival and overall survival. 
Histological examination 
Hematoxylin and eosin (HE)-stained slides of 74 tissue samples were systematically reviewed 
for morphological criteria. These histological features were: general morphological growth 
pattern, cellularity, nuclear pleomorphism, mitoses, necrosis, vascular proliferation, 
eosinophilic granular bodies or Rosenthal fibers and infiltration pattern. 
Immunohistochemistry 
For cases with available tissue, immunohistochemistry with antibodies binding to ATRX (n=54), 
H3 K27M (n=47), IDH1 R132H (n=45) or BRAF V600E (n=51) was performed on a Ventana 
BenchMark XT Immunostainer (Ventana Medical Systems, Tucson, Arizona, USA) using 
established protocols. For dilutions and antibody details, see Supplementary Table 1. 
Immunostaining with antibodies against BRAF V600E, IDH1 R132H and H3 K27M was scored 
as either positive or negative. For all three antibodies, nonspecific staining of macrophages, 
eosinophilic granular bodies and calcified deposits was excluded from analysis. Staining of 
vessels or reactive glia was also not considered. Loss of nuclear ATRX expression was scored 
as specific, if over 80% of tumor cell nuclei showed loss of expression, while nuclei of non-
neoplastic cells, such as endothelia, microglia, lymphocytes and reactive astrocytes, were 
positive. Of note, weak to moderate staining of tumor cell cytoplasm was occasionally seen 
and was considered as non-specific [40]. Slides were scanned on a NanoZoomer Digital Slide 
Scanner (Hamamatsu, Hamamatsu, Japan) and photographed using Aperio ImageScope 
software (v11.0.2.725, Aperio Technologies, Vista, California, USA). 
DNA extraction and quantification 
DNA was extracted from FFPE tissue using the automated Maxwell system (Promega, 
Fitchburg, Massachusetts, USA) according to the manufacturer’s instructions. DNA 
concentration was determined using the Qubit dsDNA BR Assay kit (Invitrogen, Carlsbad, 
California, USA) following the producer’s guidelines.  
Generation of DNA methylation array data, copy number profile calculation, 
determination of MGMT promoter methyltation status 
From each tissue sample, 200 to 500 ng of DNA were processed for DNA methylation analysis. 
The Infinium HumanMethylation450 Bead-Chip (450k) array (Illumina, Carlsbad, California, 
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USA) was used to determine the DNA methylation status of 482421 CpG sites according to 
the manufacturer’s instructions at the Genomics and Proteomics Core Facility of the German 
Cancer Research Center (DKFZ). A copy number profile (CNP) was calculated from the 
methylation array data as previously described [20] using the ‘conumee’ package in R 
(http://bioconductor.org/packages/release/bioc/html/conumee.html). MGMT promoter 
methylation status was determined from the methylation array data as described [5]. 
Amplifications in DNA copy number profile were defined as focal regions of copy number gain 
with a notably higher amplitude than regions of suspected single-copy gains. 
H3F3A, BRAF, IDH1, IDH2 and TERT promoter mutation analysis by Sanger sequencing 
Primer design and sequencing were performed according to standard protocols. Primer 
sequences and NM accession numbers for the respective genes are listed in Supplementary 
Table 2. For the amplification reaction, the following reagents were used:  12,5 µl of Go Taq 
G2 DNA polymerase (Promega), 1.25 µl forward primer (10 pmol/µl), 1.25 µl reverse primer 
(10 pmol/µl), 8.0 µl nuclease free water and 2 µl template DNA (approximately 25 ng/µl). PCR 
conditions are listed in Supplementary Table 3. 
MGMT promoter pyrosequencing 
For cases with indeterminable MGMT promoter methylation status by 450k methylation 
analysis, additional pyrosequencing was performed using the therascreen® MGMT Pyro® kit 
(QIAGEN®) and the PyroMark® Q24 system (QIAGEN®) according to the manufacturer’s 
protocol. Bisulfite conversion was done with the EpiTect fast DNA bisulfite kit (QIAGEN®). 
According to a studies published by Quillien et al., Felsberg et al. and Reifenberger et al. [12, 
36, 38], the cutoff value for MGMT promoter methylation status was set as follows: a mean 
MGMT promoter methylation percentage < 8% across the investigated CpG sites was 
considered as non-methylated and a value ≥ 8% was considered as methylated. 
Gene panel sequencing 
Gene panel sequencing was performed and resulting data were analyzed as previously 
described [45]. In brief, extracted DNA was sheared on a M220 Focused-ultrasonicator™ 
(Covaris®, Woburn, Massachusetts, USA). DNA integrity and fragment size were determined 
by the Bioanalyzer 2100 (Agilent, Santa Clara, California, USA). Sequencing was performed 
on a NextSeq 500 instrument (Illumina, Carlsbad, USA) with a mean coverage of 645 reads 
and a standard deviation of 455 reads. Gene panel sequencing data were automatically 
annotated using annovar software that integrates information from databases such as dbSNP, 
the 1000 Genomes Project and COSMIC, as well as with SIFT and PolyPhen2 scores to infer 
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the possible biological relevance of an alteration [53]. Gene panel sequencing data were then 
filtered applying the following criteria: firstly, exonic and splicing variants were selected. From 
these, synonymous and stoploss variants were not further considered. Thereafter, variants 
with a frequency not exceeding 1% in the healthy population as well as undescribed variants 
were selected according to the 1000 Genomes Project database. Variants described as known 
polymorphisms in the Single Nucleotide Polymorphism database (dbSNP, version 138:  
https://www.ncbi.nlm.nih.gov/projects/SNP/snp_summary.cgi?view+summary=view+summar
y&build_id=138) were not considered. Insertions and deletions were filtered for exonic 
frameshift changes that were not yet detected in the healthy population according to the 1000 
Genomes Project database and that were not present in the Single Nucleotide Polymorphism 
database (dbSNP). The remaining items (nonsynonymous, stopgain or splicing site variants, 
frameshift insertions and frameshift deletions) were evaluated for their potential clinic-
pathological relevance using the COSMIC database (http://cancer.sanger.ac.uk/cosmic) and 
the ClinVar database (http://www.ncbi.nlm.nih.gov/clinvar/) and categorized with regard to the 
probable consequences on protein function: damaging, possibly damaging, likely not relevant 
or no applicable information. Variants assessed as damaging or possibly damaging were 
considered as mutations. Variants assessed as likely not relevant or with lack of information 
about clinical relevance were not considered. For determining the MAPK pathway status, we 
considered the following genes: NF1, BRAF, FGFR1, KRAS, NRAS, HRAS, NTRK2 and 
PTPN11. A full list of the genes represented in the applied gene panel is provided in 
Supplementary Table 4. 
Reference datasets 
Reference datasets for t-SNE, clustering and copy number analyses: for t-SNE and 
hierarchical clustering, the following glioma reference classes were included: diffuse midline 
glioma, H3 K27 mutant (DMG K27; 14 cases); high-grade neuroepithelial tumor, H3 G34 
mutant (GBM G34; 11 cases); GBM of the midline (GBM MID; 10 cases); GBM, mesenchymal 
subtype (GBM MES; 15 cases); GBM, RTK I subtype (GBM RTK I; 15 cases); GBM, RTK II 
subtype (GBM RTK II; 8 cases), pleomorphic xanthoastrocytoma (PXA; 17 cases), PA of the 
supratentorial hemispheres (PA SUP; 12 cases), PA of the posterior fossa (PA PF; 15 cases), 
PA of the midline (PA MID; 18 cases), dysembryoplastic neuroepithelial tumor (DNET; 13 
cases) and diffuse leptomeningeal glioneuronal tumor (DLGNT; 10 cases). 
Detailed descriptions of the reference methylation classes used in this study are outlined under 
the following link: https://www.molecularneuropathology.org/mnp/classifier/2 
Reference sets for the Kaplan Meier analysis: Outcome data were available for 41 of the MC 
APA patients. For patients with an initial diagnosis of a lower-grade glioma, the date of the first 
histological diagnosis of anaplasia was considered as starting point for the outcome analysis. 
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Kaplan Meier analysis was performed in comparison to survival data from additional 281 
glioma patients of 5 reference classes: 82 PAs WHO grade I, 18 PXAs, 26 anaplastic 
astrocytomas, IDH mutant (AIII IDH mut), 90 GBMs, IDH mutant (GBM IDH mut) and 56 GBMs, 
IDH wildtype (GBM IDH wt).  
Statistical analyses 
The DNA methylation array data were processed with the R/Bioconductor package minfi 
(version 1.20) [3]. For unsupervised hierarchical clustering of APAs and reference samples, 
we selected the 20,000 most variably methylated CpG sites across the dataset according to 
median absolute deviation. Pairwise similarity of samples was calculated using Euclidean 
distance. Clusters were then linked according to the Ward’s linkage method. t-SNE plot was 
computed via the R package Rtsne [28] using the 20,000 most variable CpG sites according 
to standard deviation, 2,000 iterations and a perplexity value of 20. To define the DNA 
methylation class APA, cutoffs for the X and the Y values were deduced from the t-SNE plot 
(Fig 1) as follows: -10 < Y < 10 and -20 < X < 2. Survival data of APA patients and reference 
group patients were evaluated via Kaplan-Meier analysis using the JMP software (SAS 
Institute, Cary, North Carolina, USA). To verify differences of the survival distributions between 
the respective patient groups, the Log-rank test was applied.  
Results 
APA form a distinct DNA methylation class  
We performed DNA methylation analysis of 102 gliomas with a histological differential 
diagnosis of APA. t-SNE analysis of their DNA methylation profiles against 158 reference 
cases from 12 different established glioma DNA methylation classes revealed a distinct DNA 
methylation class comprising 83 of these 102 tumors (81%; Fig 1). Subgroups did not become 
apparent in the t-SNE analysis. The 19 remaining tumors were congruent with or close to one 
of the reference classes. Two of these showed a high similarity to high-grade glioma reference 
classes (one to DMG K27 and the other to GBM MID), two to the PXA reference class and 15 
cases were similar to the low-grade glioma reference classes comprising PAs and DNETs. 
The 83 tumors in the APA group, henceforth designated as DNA methylation class APA (MC 
APA), were further characterized by including clinical and molecular features. Of note, the MC 
APA also contained two tumors with a H3 K27M mutation. Indeed, these lesions were located 
near the midline (one in the third and lateral ventricle and the other in the cerebellum), but did 
not otherwise show histological features of DMG K27, as both cases had a piloid morphology. 
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In addition, we performed clustering analysis of the cohort previously analyzed by t-SNE 
(Supplementary Fig 1). This analysis revealed a cluster of 81/83 APAs which were congruent 
with the tumors of the MC APA identified by t-SNE confirming the assignment as a distinct 
molecular entity. Within this methylation cluster, two subclusters (a and b, see Supplementary 
Fig 1) were putatively identified. There was, however, no high consistency in repeated 
clustering analyses and no obvious clinical, histological or molecular differences were seen 
between the two subclusters. 
Re-classification of tumors with histological features of APA, but divergent DNA 
methylation profile  
t-SNE and clustering analysis revealed that 19 of the 102 tumors with histological features of 
APA displayed a DNA methylation profile that differed from the MC APA (Fig 1 and 
Supplementary Fig 1). In keeping with our experience with other series [50] (Capper et al.: 
“DNA methylation-based classification of human central nervous system tumours”, under 
revision), the majority of these tumors could be re-classified on the basis of re-evaluation of 
histology and orthogonal molecular findings (immunohistochemistry for BRAF V600E, H3 
K27M, ATRX, copy number profile analysis): six tumors were downgraded to PA WHO grade 
I, one case was re-classified as PXA, one as diffuse midline glioma with H3 K27M mutation, 
one as GBM, IDH wildtype and two as low grade gliomas, not otherwise specified (NOS). The 
remaining eight cases could not be concretely classified. Supplementary Table 5 and 
Supplementary Fig 2 and 3 give details and show examples of re-classified and non-
classifiable cases. 
Clinical characteristics of the MC APA 
The tumors in the MC APA (n=83) were preferentially located in the posterior fossa (74%), 
most frequently in the cerebellum (63%). 17% were located supratentorially, two cases (2%) 
had a supra- as well as infratentorial localization and 5 cases (7%) were located in the spinal 
compartment (Fig 2a). Median patient age at resection was 41.5 years with only 8 out of 76 
tumors (11%) occurring in patients below the age of 20 years (Fig 2b). The distribution of male 
and female patients was balanced (male female ratio of 1.1; n=83). Of 67 patients with 
available data, 42 patients (63%) presented as primary diagnosis without previously known 
lesions, whereas the investigated tumors of 25 patients (37%) represented recurrences (Fig 
2c) from either low-grade primary tumors (8 cases, 12%), primary APA (3 cases, 4%) or 
primary tumors with unknown initial grade (14 cases, 17%). Among the 8 patients with an 
initially low-grade tumor, 6 had an initial diagnosis of PA, while the remaining two patients were 
initially diagnosed as oligodendroglioma WHO grade II and diffuse astrocytoma WHO grade 
II. For the 25 recurrent lesions, relapses occurred within 10 years in 18 cases (72%), whereas 
time to relapse was longer than 10 years in four cases (16%) and was unknown for another 
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three cases (12%). Median overall survival after primary diagnosis with APA was 24 months 
(n=41). Median time to progression was 1.2 years with a wide variation ranging from 66 days 
up to 28.3 years. For patients with a low-grade primary tumor, median time to recurrence was 
3.2 years (n=6), whereas in patients with a high-grade primary tumor, median time to 
progression was only 0,9 years (n=3). For only 5% (4 cases) of the patients in the whole cohort, 
previous irradiation was reported. A diagnosis of neurofibromatosis type 1 was clinically known 
in one patient and clinically suspected in a second patient. Other hereditary tumor 
predisposition syndromes were not reported.  
Histological and immunohistochemical findings in APA 
We were able to comprehensively evaluate 74 cases of the MC APA histologically including 
the assessment of growth and infiltration pattern, cellularity, nuclear pleomorphism, mitotic 
count, presence of necrosis, vascular proliferation and presence of eosinophilic granular 
bodies and/or Rosenthal fibers. Results are summarized in Fig 3. Examples for histological 
features of the MC APA are shown in Fig 4a, 4b and 4c. 
Immunohistochemical analysis included assessment of the glioma markers ATRX, BRAF 
V600E, H3 K27M and IDH1 R132H. In 44% (24/54) of APAs nuclear ATRX expression was 
lost in the tumor cells (Fig 4d). BRAF immunohistochemistry revealed only one positive case 
(1/51, 2%). By H3 K27M immunohistochemistry and confirmatory Sanger sequencing analysis, 
one case (1/47, 2%) with a H3 K27M mutation was identified (Supplementary Fig 4). For all 
the remaining cases tested by immunohistochemistry, H3 K27M (Fig 4e) and BRAF V600E 
were negative. Notably for this group of non-GBM diffuse gliomas, IDH1 R132H 
immunohistochemistry was negative in all cases investigated (45/45) (Fig 4f).  
Molecular characteristics of the MC APA - CDKN2A/B deletion represents the most 
frequent structural aberration of APA 
Copy number profile analysis of the molecular APA series disclosed numerous, partially 
complex chromosomal alterations: in 73 of 83 cases (88%), more than three structural 
aberrations were found, whereas a small subset of 10 cases (12%) exhibited three or fewer 
alterations. Fig 5a illustrates a representative low-grade posterior fossa PA copy number 
profile, whereas in Fig 5b, an example of a copy number profile for a tumor of the MC APA is 
shown. Fig 5c and d show the averaged copy number profiles of 45 PA reference cases 
(comprising 15 cases of posterior fossa PA, 18 cases of midline PA and 12 cases of 
supratentorial PA) and from all 83 tumors of the MC APA. The most frequent aberration in the 
MC APA (66/83 cases, 80%) was a deletion of CDKN2A/B. This was frequently associated 
with broader deletions or complex changes on chromosome arm 9p (41/83 cases, 49%). A 
further significant finding was a BRAF fusion indicated by a focal peak on chromosome 7q in 
13 
 
15 out of 74 assessed cases (20%) (Fig 5b, 5d, 6). Other recurrent copy number aberrations 
were gains and/or complex changes on chromosome arms 12q (27%) and 17q (33%) as well 
as deletions on chromosomes 1p (19%), 8p (23%) and 19q (22%). A CDK4 amplification was 
detected in seven cases (8%) and this was associated with a concomitant MDM2 amplification 
in four cases (5%). Other recurrent amplifications more commonly seen in GBM (e.g. of MDM4, 
PDGFRα, EGFR, CDK6, MET) were not observed. 
APAs harbor mutations in MAPK pathway genes 
Alterations affecting genes encoding members of the mitogen-activated protein kinase (MAPK) 
pathway have previously been found to occur in up to 100% of WHO grade I PAs [22-24]. By 
combining immunohistochemistry, panel sequencing and copy number analysis, we were able 
to comprehensively examine the status of MAPK pathway gene alterations for 65 of 83 tumors 
of the MC APA (Fig 6). In 49 out of these 65 cases (75%), at least one characteristic MAPK 
pathway gene alteration was detected. In notable contrast to typical PAs, the most frequently 
affected gene was NF1, being altered in 20 of 67 lesions (30%). In total, five tumors exhibited 
a deletion, 10 cases harbored a mutation (including one clinically known NF1 syndrome 
patient) and three cases showed both, a deletion in the copy number profile and a mutation of 
the NF1 gene. The remaining two cases showed immunohistochemical loss of NF1 protein 
expression and a balanced NF1 gene dosage in the copy number profile. BRAF was the 
second most frequently altered MAPK pathway gene: 15 of 74 cases (20%) harbored a BRAF 
fusion and one case (1%) a BRAF V600E mutation. In 12 out of 64 cases (19%) an FGFR1 
alteration was detected. Among these, 11 of 64 tumors (17%) had a point mutation at one of 
the known hotspots (K656E/N, N546D/K) and one case (2%) exhibited an FGFR1/TACC1 
fusion. In another two of 64 cases (3%) a KRAS point mutation (Q61H in one and V14A in the 
other) was detected (Fig 6). MAPK pathway gene alterations were mutually exclusive with the 
exception of one case harboring both an NF1 and an FGFR1 alteration (Fig 6).  
APAs frequently display ATRX, but rarely TERT alterations 
Alterations in mechanisms of telomere maintenance are well known drivers of tumor 
progression in a variety of entities. In particular, TERT promoter and ATRX mutations are 
frequently described in diffuse gliomas and have been established as useful markers for their 
classification and prognostication [35, 39, 40]. Unexpectedly, we found a high rate of ATRX 
alterations in the MC APA: in 15 of 64 tumors (23%) mutant ATRX was detected by panel 
sequencing and 24 of 54 tumors (44%) showed an immunohistochemical loss of nuclear ATRX 
expression. For 21 of these 24 cases, panel sequencing data were also available: in these, a 
relevant ATRX mutation was confirmed in 12 cases (57%). In the 18 cases with retained 
nuclear ATRX expression and with available panel sequencing data, no ATRX mutations were 
detected. The sensitivity of our gene panel sequencing approach to predict ATRX protein loss 
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was thus 57%, the specificity being 100%. In a study on IDH mutant gliomas, ATRX gene 
alterations were also not found in a subset of cases with a loss of nuclear ATRX expression. It 
appears likely that other mechanisms than exonic mutations may also result in a functional 
(and immunhistochemical) loss of ATRX protein [56].  
ATRX alterations and TERT promoter mutations are known to occur in a mutually exclusive 
manner in gliomas [25, 40]. To determine the rate of TERT promoter mutations in the MC APA 
and to explore, whether these are mutually exclusive with ATRX alterations in this newly 
defined tumor class, we performed Sanger sequencing of the TERT promoter region of 74 
tumors of the MC APA from which 31 cases carried an ATRX alteration (Fig 6). Two tumors 
(3%) with a TERT promoter mutation, both with the nucleotide exchange C228T, were 
identified. Both tumors did not harbor an ATRX alteration. While gain of chromosome 5p was 
observed in approximately 10% of APAs, no focal TERT amplifications were seen (Fig. 5c). 
MGMT promoter hypermethylation is a frequent finding in APAs 
In 38 out of 83 tumors of the MC APA (46%), the MGMT promoter was hypermethylated, 
another 38 tumors (46%) showed a non-methylated MGMT promoter and in seven tumors 
(8%), the MGMT promoter methylation status could not be determined (Fig 6). 
Comparison of the MC APA with the molecular subtypes of glioma previously 
described by Ceccarelli et al. 
A subset of adult diffuse IDH wildtype gliomas showing a DNA methylation profile distinct from 
the classic-like and mesenchymal-like GBM defined by Sturm et al. [51] has recently been 
described by a pan-glioma analysis of The Cancer Genome Atlas (TCGA) data [8]. This subset 
of tumors has been shown to be further subdivided into two DNA methylation subclasses, from 
which one shows similarity to GBM and the other to PA. These DNA methylation subclasses 
have been designated “LGm6-GBM” and “PA like low-grade gliomas” (LGG) [8]. DNA 
methylation profiles of the MC APA and the PA-like LGG subset of tumors from the TCGA 
series were re-analyzed together with the reference classes described above by t-SNE (Figure 
7). While 3 of 27 and 14 of 27 TCGA tumors clustered more closely with our GBM and our low-
grade glioma reference classes, the DNA methylation profiles of a subset of 9 of 27 TCGA 
cases showed high similarity to the MC APA. Interestingly, these tumors were also enriched 
for NF1- or BRAF alterations, CDKN2A/B loss and/or ATRX mutation [8] further confirming that 
these tumors may likely represent a distinct molecular entity. 
Outcome analyses  
Outcome data were available for 41 of the 83 patients with a MC APA tumor: at the date of the 
last follow-up, 18 patients (44%) had deceased, and 23 patients (56%) were alive. Median 
overall survival was 720 days (approximately 24 months). Kaplan Meier analysis of these 41 
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patients against five glioma reference classes showed a survival probability inferior to patients 
with conventional PA, PXA and IDH mutant anaplastic astrocytoma and comparable to patients 
with IDH mutant GBM, but superior to patients with IDH wildtype GBM (Fig 8a). Of note, 
univariate outcome analysis of patients of the MC APA with a proven characteristic MAPK 
pathway gene alteration compared with patients without such an alteration showed a 
significantly worse prognosis for the latter (p=0.032, Fig 8b), suggesting that non-canonical 
alterations may be associated with more aggressive clinical behavior. Kaplan-Meier analysis 
for each individual MAPK pathway gene alteration alone was also performed and showed no 
significant differences of survival probabilities between patients with BRAF, NF1 or FGFR1 
altered tumors and patients negative for a characteristic MAPK pathway gene alteration 
(Supplementary Fig 5). No significant outcome differences were seen in patients with MGMT 
methylated versus non-methylated tumors (p=0.922) as well as in patients with ATRX altered 
versus ATRX wildtype tumors (p=0.685) (Fig 8c, d). Furthermore, outcome analysis dependent 
on histological criteria (presence/absence of necrosis, mitotic count) was performed (n=38). 
No significant difference in survival probability between tumors with versus without necrosis 
(p=0,468) or with 1-2 versus more than 2 mitoses (p=0,383) was evident (see Supplementary 
Fig 6).  
Discussion 
In this study we report a novel class of glial tumors defined by a characteristic DNA methylation 
profile and harboring many cases with a morphological overlap with PA with anaplasia as 
described in the WHO classification 2016 [1]. However, detailed histological evaluation shows 
a wide range of morphological features that would occasionally be more in keeping with other 
tumor entities (especially high-grade glioma/GBM). Thus, as with a growing number of CNS 
tumors, the tumor class of APA as defined here by DNA methylation profiling (MC APA) is not 
exactly congruent with PA with anaplasia as defined in the current WHO classification [1]. 
Initially, t-SNE and cluster analysis of the DNA methylation profiles were performed and 
consistently revealed a distinct DNA methylation cluster denoted MC APA. The closest 
resemblance of the DNA methylation profiles of these tumors was evident with the reference 
DNA methylation class of diffuse leptomeningeal glioneuronal tumor (DLGNT) (Fig 1, 
Supplementary Fig 1). Indeed, these tumors may be closely related to APA, since they also 
frequently harbor BRAF fusions in conjunction with other alterations not found in classical PA 
(e.g. 1p loss) [7].  
Our further investigations focused on the clinical, histological and molecular characterization 
of the MC APA. As it has previously been reported for a series of histologically defined APAs 
[42], we observed a higher median patient age in the MC APA than in conventional PA [6]. In 
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fact, the gliomas belonging to the MC APA mostly arise in adults. Only 8% of these tumors 
occurred in patients less than 18 years of age. The most frequent tumor localization in our 
series was the posterior fossa (74%) with 63% of the tumors originating from the cerebellum. 
Compared to a previously reported series of histologically defined APAs [42], the posterior 
fossa location seems even more frequent among gliomas of the MC APA. Importantly, clinical 
history of radiotherapy was reported in only 5% (4/83) of the patients. Thus, the role of 
irradiation in the progression to APA, as reported previously, may require additional 
investigation [2, 42].  
As shown in Fig 3, we observed a wide spectrum of histological features in our series:  most 
of the tumors in the MC APA showed a piloid or GBM-like general morphological pattern, were 
moderately cellular, had moderate nuclear pleomorphism, at least 1 mitosis per 10 HPF and 
microvascular proliferation. Around one third of the tumors exhibited areas of necrosis and one 
third showed eosinophilic granular bodies or Rosenthal fibers, respectively. In summary, 
morphological characteristics of the MC APA were not particularly specific and may overlap 
with other low and high-grade gliomas. Despite a small subset of cases showing typical 
histological features of anaplasia, our investigations revealed that the histology of the majority 
of cases in our series appears rather inconspicuous. Thus, molecular analysis may be required 
in order to come to a final, integrated diagnosis. With regard to immunohistochemistry, the 
most interesting finding was a loss of nuclear ATRX expression. Comparison of 
immunohistochemical ATRX staining of tumors in the MC APA and a control cohort of 
conventional PAs showed that ATRX loss is restricted to the former. In keeping with our results, 
Ebrahimi et al. did not detect ATRX alterations in conventional PAs, but identified one case of 
APA and one case of BRAF-fused cerebellar GBM with loss of ATRX expression [11]. 
MGMT promoter methylation status has been shown to have predictive and prognostic value, 
particularly for patients with GBM [15, 27, 31]. This study revealed that MGMT promoter 
hypermethylation was present in approximately half of APAs, whereas in a control cohort of 
conventional PAs, the MGMT status was either non-methylated in most of the cases or 
intermediate in a small subset of tumors. These data indicate that MGMT promoter methylation 
status may be of diagnostic relevance in terms of distinguishing conventional PA from APA. 
However, the present data do not provide any evidence for an association of MGMT promoter 
methylation status with OS amongst the MC APA. Admittedly, the prognostic value of this 
outcome analysis is limited, as clinical information about a previous chemotherapy and the 
applied pharmaceuticals (e.g. temozolomide) were incomplete. 
Another important finding of this study was that the distribution of MAPK pathway gene 
alterations in the MC APA clearly differed from that known for conventional PA. For instance, 
BRAF fusions are known to be the most abundant molecular alteration in conventional PAs 
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with a frequency of up to 75%, depending on tumor localization and patient age. The second 
most common alterations in approximately 7% of PAs affect the NF1 gene, followed by 
activating BRAF mutations (5%) and FGFR1 hotspot mutations (5%). Rarely (about 1 up to 
2% each) NTRK2 fusions, PTPN11 mutations and RAF1 fusions were also found [22, 24]. In 
contrast, with a frequency of only 20%, BRAF fusions are surprisingly rare in the MC APA, 
whereas NF1 turned out as the most frequently affected gene being altered in 30% of the 
tumors. Furthermore, a substantial fraction (16%) of tumors harbored a FGFR1 hotspot 
mutation and in one tumor, a FGFR1/TACC1 fusion was detected, as previously reported in 
pediatric low-grade as well as in high-grade gliomas. This aberration has also been shown to 
transform primary astrocytes into highly proliferating glial tumors [47, 57]. NTRK2 fusions, 
PTPN11 mutations or RAF1 fusions were not found and a KRAS mutation was detectable in 
only two cases (2%). FGFR1 alterations have been described to be preferentially found in 
extra-cerebellar and especially in midline gliomas [9, 24]. However, in the present series, the 
majority of FGFR1 mutant cases were located in the posterior fossa (Fig 6). Hence, these data 
indicate that FGFR1 alterations may not be restricted to extracerebellar or midline locations. 
BRAF alterations have been described to be less frequent (36% of cases) in adult compared 
to juvenile PAs [34]. In a study conducted by Hasselblatt et al., comparable results were 
obtained with a fraction of BRAF fusions of 30% in patients aged 31-40 years and of 7% in 
patients older than 40 years [17]. As also the MC APA proved to be characterized by a higher 
patient age, the age distribution of BRAF fusions may explain the comparably low fraction of 
tumors positive for a BRAF fusion in the present series. We furthermore observed that 
CDKN2A/B deletion in a BRAF fusion positive astrocytic glioma is highly suggestive for the 
diagnosis of APA and makes the diagnosis of WHO grade I PA less likely. 
Aberrant activation of the MAPK pathway in PA, particularly by BRAF or RAS activation and 
NF1 inactivation, is thought to trigger oncogene-induced senescence (OIS) via engagement of 
the cyclin dependent kinase inhibitors p16Ink4a and/or p21Waf1. As these proteins trigger cell 
cycle arrest, they are known as tumor suppressors and are supposed to be associated with 
the indolent biological and clinical behavior of conventional PAs [22]. Rodriguez et al. observed 
a loss of p16 in a subset of PAs with anaplastic features [41]. Another study revealed that PA 
patients with immunohistochemical loss of p16 expression had a shorter overall survival than 
PA patients with retained p16 expression [37]. These findings raised the question, whether the 
prognosis of patients with PA/APA may be associated with the presence or absence of p16. 
Approximately half of the cases comprising the MC APA displayed a MAPK pathway gene 
alteration in combination with a CDKN2A/B deletion. For these lesions, impairment of OIS may 
be assumed. We hypothesized that impaired OIS may at least in part contribute to the adverse 
clinical course of APA. From 26 patients with MAPK pathway gene altered and CDKN2A/B 
deleted tumors and with available survival data, 10 (38%) were indicated as deceased and 16 
18 
 
(62%) as alive with a median overall survival of 604 days. Independent of MAPK status, 
patients with CDKN2A/B deleted tumors had a median overall survival of 618 days (n=37), 
whereas patients with tumors with balanced CDKN2A/B copy number had a median overall 
survival of 1072 days (n=4).  Further studies with a higher case number are required to 
particularly determine the impact of CDKN2A/B deletions on survival of (MAPK pathway gene 
altered) APAs. 
Existence of anaplastic features in PA has previously been found to be associated with 
decreased overall survival. In one series outcomes of APA patients were indeed less favorable 
in comparison to conventional PA patients. Survival data were stated as comparable to WHO 
grade II and III diffusely infiltrative astrocytomas, but still better than grade WHO IV GBMs [42]. 
Another study suggested that APA patients may have a better prognosis than other high-grade 
gliomas in adult patients [13]. However, Kaplan Meier analysis of patients with molecularly-
defined APAs (MC APA) in the present series revealed a survival probability worse than 
patients with IDH mutant anaplastic astrocytoma, WHO grade III and comparable to patients 
with IDH mutant GBM, WHO grade IV (although better than patients with IDH wildtype GBM, 
WHO grade IV). Median overall survival of approximately 24 months (720 days) was consistent 
with the results of other authors [42]. Notably, the comparability of the outcome data discussed 
above may be limited, as cases for previously performed analyses were selected by 
histological criteria, whereas for the present series, molecular data were additionally taken into 
account and may have led to a higher discrimination selectivity with respect to other glioma 
entities. Another notable finding of this study was that patients with tumors harboring a 
characteristic MAPK pathway gene alteration were found to survive significantly longer than 
patients with tumors carrying no characteristic MAPK pathway gene alteration. Further 
analyses, such as RNA and whole-exome sequencing, are required to investigate alternative 
alterations in the latter tumors and, when indicated, to reappraise, whether the absence of 
MAPK pathway gene alterations in APA may indeed be associated with a worse outcome.  
In conclusion, APA, PA WHO grade I, PXA and to some extent GBM may show overlapping 
histological and/or molecular features. Importantly, PXAs are also known to show alterations 
in BRAF as well as CDKN2A/B [26, 54] and PAs may also harbor BRAF fusions [17, 21, 22]. 
Hence, the distinction between these three entities may become challenging [29]. Fig 9 
provides a suggestion of a diagnostic algorithm in case APA is suspected. As indicated, 
immunohistochemical and single parameter molecular analysis may at least help to exclude 
other glioma classes. Nonetheless, comprehensive molecular investigations (such as DNA 
methylation profiling and/or gene panel sequencing) are recommended to definitely confirm 
this diagnosis. As defined in the present study, APA is characterized by a distinct DNA 
methylation profile and alterations of NF1, BRAF or FGFR1 together with CDKN2A/B and 
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ATRX loss as well as MGMT promoter hypermethylation. Further investigations will be required 
to compile a set of molecular markers to underpin the diagnosis of APA, in order to cement its 
position in brain tumor classifications and enable, for example, reliable stratification of clinical 
trials. 
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